Table 4.
OCT -derived study endpoints
| Standard of care (N = 31) |
Alirocumab (N = 30) |
P Value | |
|---|---|---|---|
| Minimum fibrous cap thickness, um | |||
| Baseline | 116.4 (90.1 to 136.2) | 126.0 (87.5 to 145.5) | 0.44 |
| After 36 weeks treatment | 124.2 (98.2 to 144.3) | 144.0 (111.5 to 151.8) | 0.049 |
| Changes from baseline | 13.2 (7.4 to 18.6) | 18.0 (10.8 to 29.2) | 0.029 |
| Maximum lipid arc, degree | |||
| Baseline | 110.9 (90.2 to 132.4) | 109.6 (89.8 to 130.0) | 0.53 |
| After 36 weeks treatment | 102.2 (87.0 to 123.1) | 93.5 (77.5 to 108.1) | 0.19 |
| Changes from baseline | −8.4 (−2.0 to −10.5) | −15.1 (−7.8 to − 24.5) | 0.008 |
| Minimum lumen area, mm2 | |||
| Baseline | 2.47 (2.20 to 2.74) | 2.32 (2.07 to 2.63) | 0.22 |
| After 36 weeks treatment | 2.60 (2.19 to 2.90) | 2.57 (2.27 to 2.90) | 0.77 |
| Changes from baseline | 0.13 (0.12 to 0.24) | 0.20 (0.10 to 0.33) | 0.006 |
| TCFA, %(n) | |||
| Baseline | 25.8 (8) | 20.0 (6) | 0.59 |
| After 36 weeks treatment | 16.1 (5) | 3.3 (1) | 0.09 |
TCFA thin-cap fibroatheroma